skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines omalizumabQuestion & answer

omalizumab · Medicine question

What is known about the effects of omalizumab on human fertility?

iatroX medicinesPublished 8 November 2026

The answer

Answer

There are no human fertility data for omalizumab.

Sources for this answer

Xolair 150mg Solution for Injection in pre-filled syringeNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 22Document updated 13 March 2024

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

omalizumab

More questions about omalizumab

Can omalizumab reduce the effectiveness of medicines used to treat parasitic infections?From what age is Xolair (omalizumab) indicated for severe persistent allergic asthma?What is Xolair (omalizumab) used for in adults with severe chronic rhinosinusitis with nasal polyps inadequately controlled by intranasal corticosteroids?What latex-related warning applies to the needle cap of the Xolair (omalizumab) 150 mg pre-filled syringe?What were the most commonly reported adverse reactions to omalizumab in allergic asthma trials involving children aged 6 to 11 years?

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the omalizumab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX

What were the most commonly reported adverse reactions to omalizumab in allergic asthma trials involving patients aged 12 years and older?